TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company focused on RNA-based therapeutics for cancer, announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the execution of a sponsored research agreement with Michigan State University. These developments are aimed at advancing the company's pipeline of RNA-based therapies for treating advanced cancers.
Dr. Moore, a prominent researcher in molecular imaging and nanomedicine, will provide strategic guidance on TransCode's research and development efforts. Her expertise is expected to help steer the company's programs, particularly its lead candidate TTX-MC138, which targets metastatic tumors that overexpress microRNA-10b—a biomarker strongly associated with metastasis. The sponsored research agreement with Michigan State University will support the further development of TTX-MC138, including evaluation in combination with other therapies.
The company's lead therapeutic candidate, TTX-MC138, is designed to treat metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. TransCode also has a portfolio of other first-in-class therapeutic candidates aimed at mobilizing the immune system to recognize and destroy cancer cells. The collaboration with Michigan State University is expected to accelerate the preclinical and clinical development of these therapies.
This news is significant for the biotech industry and cancer patients, as it underscores the growing focus on RNA-based therapies to address high-risk and advanced cancers. Metastatic cancer remains a major challenge in oncology, and treatments that target specific biomarkers like microRNA-10b could offer new hope for patients with limited options. The appointment of Dr. Moore and the research agreement with Michigan State University may enhance TransCode's ability to bring novel therapies to the clinic.
Investors should note that the latest news and updates regarding RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. The full press release can be accessed at https://ibn.fm/NA2NH.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA for the treatment of high-risk and advanced cancer. The company's lead candidate, TTX-MC138, and its pipeline of other candidates represent a novel approach to cancer treatment by targeting the underlying mechanisms of metastasis and immune evasion. The collaboration with Michigan State University and the appointment of Dr. Moore are strategic steps to advance this pipeline.
